Patients With NASH and Cryptogenic Cirrhosis Are Less Likely Than Those With Hepatitis C to Receive Liver Transplants
Background & Aims Many patients with cryptogenic cirrhosis (CC) have other conditions associated with nonalcoholic steatohepatitis (NASH) that put them at risk for complications that preclude orthotopic liver transplantation (OLT). Methods We followed all patients with NASH and CC who were evalu...
Gespeichert in:
Veröffentlicht in: | Clinical gastroenterology and hepatology 2011-08, Vol.9 (8), p.700-704.e1 |
---|---|
Hauptverfasser: | , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 704.e1 |
---|---|
container_issue | 8 |
container_start_page | 700 |
container_title | Clinical gastroenterology and hepatology |
container_volume | 9 |
creator | O'Leary, Jacqueline G Landaverde, Carmen Jennings, Linda Goldstein, Robert M Davis, Gary L |
description | Background & Aims Many patients with cryptogenic cirrhosis (CC) have other conditions associated with nonalcoholic steatohepatitis (NASH) that put them at risk for complications that preclude orthotopic liver transplantation (OLT). Methods We followed all patients with NASH and CC who were evaluated for OLT (n = 218) at Baylor Simmons Transplant Institute between March 2002 and May 2008. Data were compared with those from patients evaluated for OLT because of hepatitis C virus (HCV)-associated cirrhosis (n = 646). Results Patients with NASH and CC were older, more likely to be female, had a higher body mass index, and a greater prevalence of diabetes and hypertension, compared with patients with HCV-associated cirrhosis, but the 2 groups had similar model for end-stage liver disease (MELD) scores. NASH and CC in patients with MELD scores ≤15 were less likely to progress; these patients were less likely to receive OLT and more likely to die or be taken off the wait list because they were too sick, compared with patients with HCV-associated cirrhosis. The median progression rate among patients with NASH and CC was 1.3 MELD points per year versus 3.2 MELD points per year for the HCV group ( P = .003). Among patients with MELD scores >15, there were no differences among groups in percentage that received transplants or rate of MELD score progression. Hepatocellular carcinoma occurred in 2.7% of patients with NASH and CC per year, compared with 4.7% per year among those with HCV-associated cirrhosis. Conclusions Patients with NASH and CC and low MELD scores have slower disease progression than patients with HCV-associated cirrhosis and are less likely to receive OLT. |
doi_str_mv | 10.1016/j.cgh.2011.04.007 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4408909</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S1542356511003879</els_id><sourcerecordid>879104959</sourcerecordid><originalsourceid>FETCH-LOGICAL-c505t-108d20b6f849979ecaab8485939997c477abdc1700a1c5223b421771c32978b03</originalsourceid><addsrcrecordid>eNp9Uk2P0zAQjRCIXRZ-ABfkG6eGceLUsZBWqiKgSBUgtoij5TjT1t00ztpJpf57JmpZAQcu_pDfe-M3b5LkNYeUA5-_26d2u0sz4DwFkQLIJ8k1L0Q2k5KLp5dzXsyLq-RFjHuATAklnydXGS8kiDK_TsZvZnDYDZH9dMOOfVncLZnpGlaFUz_4LXbOssqFsPPRRbYIyFYYI1u5e2xPbL0zHS0-4pm-xJ7kBkJWbPDsO1p0R6LQEtg6mC72raFiL5NnG9NGfHXZb5IfHz-sq-Vs9fXT52qxmtkCimHGoWwyqOebUiglFVpj6lKUhcoV3a2Q0tSN5RLAcFtkWV6LjJN3m2dKljXkN8ntWbcf6wM2lowG0-o-uIMJJ-2N03-_dG6nt_6ohYBSgSKBtxeB4B9GjIM-uGixJRfox6hLqTgIVUxIfkba4GMMuHmswkFPaem9prT0lJYGoSkt4rz583uPjN_xEOD9GYDUpKPDoKOltCw2LqAddOPdf-Vv_2Hb1lGgpr3HE8a9H0NH3ddcx0yDvpvGZZoWzgFycpb_AmrPujk</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>879104959</pqid></control><display><type>article</type><title>Patients With NASH and Cryptogenic Cirrhosis Are Less Likely Than Those With Hepatitis C to Receive Liver Transplants</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><creator>O'Leary, Jacqueline G ; Landaverde, Carmen ; Jennings, Linda ; Goldstein, Robert M ; Davis, Gary L</creator><creatorcontrib>O'Leary, Jacqueline G ; Landaverde, Carmen ; Jennings, Linda ; Goldstein, Robert M ; Davis, Gary L</creatorcontrib><description>Background & Aims Many patients with cryptogenic cirrhosis (CC) have other conditions associated with nonalcoholic steatohepatitis (NASH) that put them at risk for complications that preclude orthotopic liver transplantation (OLT). Methods We followed all patients with NASH and CC who were evaluated for OLT (n = 218) at Baylor Simmons Transplant Institute between March 2002 and May 2008. Data were compared with those from patients evaluated for OLT because of hepatitis C virus (HCV)-associated cirrhosis (n = 646). Results Patients with NASH and CC were older, more likely to be female, had a higher body mass index, and a greater prevalence of diabetes and hypertension, compared with patients with HCV-associated cirrhosis, but the 2 groups had similar model for end-stage liver disease (MELD) scores. NASH and CC in patients with MELD scores ≤15 were less likely to progress; these patients were less likely to receive OLT and more likely to die or be taken off the wait list because they were too sick, compared with patients with HCV-associated cirrhosis. The median progression rate among patients with NASH and CC was 1.3 MELD points per year versus 3.2 MELD points per year for the HCV group ( P = .003). Among patients with MELD scores >15, there were no differences among groups in percentage that received transplants or rate of MELD score progression. Hepatocellular carcinoma occurred in 2.7% of patients with NASH and CC per year, compared with 4.7% per year among those with HCV-associated cirrhosis. Conclusions Patients with NASH and CC and low MELD scores have slower disease progression than patients with HCV-associated cirrhosis and are less likely to receive OLT.</description><identifier>ISSN: 1542-3565</identifier><identifier>EISSN: 1542-7714</identifier><identifier>DOI: 10.1016/j.cgh.2011.04.007</identifier><identifier>PMID: 21570483</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Cirrhosis ; Disease Progression ; Fatty Liver ; Fatty Liver - complications ; Fatty Liver - pathology ; Female ; Follow-Up Studies ; Gastroenterology and Hepatology ; Hepatitis C ; Hepatitis C, Chronic - complications ; Hepatitis C, Chronic - pathology ; Hepatitis, Chronic - complications ; Hepatitis, Chronic - pathology ; Humans ; Liver Cirrhosis - complications ; Liver Cirrhosis - pathology ; Liver Failure - epidemiology ; Liver Failure - surgery ; Liver Transplantation ; Male ; Middle Aged ; NASH ; Non-alcoholic Fatty Liver Disease ; Severity of Illness Index</subject><ispartof>Clinical gastroenterology and hepatology, 2011-08, Vol.9 (8), p.700-704.e1</ispartof><rights>AGA Institute</rights><rights>2011 AGA Institute</rights><rights>Copyright © 2011 AGA Institute. Published by Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c505t-108d20b6f849979ecaab8485939997c477abdc1700a1c5223b421771c32978b03</citedby><cites>FETCH-LOGICAL-c505t-108d20b6f849979ecaab8485939997c477abdc1700a1c5223b421771c32978b03</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.cgh.2011.04.007$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,315,781,785,886,3551,27929,27930,46000</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21570483$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>O'Leary, Jacqueline G</creatorcontrib><creatorcontrib>Landaverde, Carmen</creatorcontrib><creatorcontrib>Jennings, Linda</creatorcontrib><creatorcontrib>Goldstein, Robert M</creatorcontrib><creatorcontrib>Davis, Gary L</creatorcontrib><title>Patients With NASH and Cryptogenic Cirrhosis Are Less Likely Than Those With Hepatitis C to Receive Liver Transplants</title><title>Clinical gastroenterology and hepatology</title><addtitle>Clin Gastroenterol Hepatol</addtitle><description>Background & Aims Many patients with cryptogenic cirrhosis (CC) have other conditions associated with nonalcoholic steatohepatitis (NASH) that put them at risk for complications that preclude orthotopic liver transplantation (OLT). Methods We followed all patients with NASH and CC who were evaluated for OLT (n = 218) at Baylor Simmons Transplant Institute between March 2002 and May 2008. Data were compared with those from patients evaluated for OLT because of hepatitis C virus (HCV)-associated cirrhosis (n = 646). Results Patients with NASH and CC were older, more likely to be female, had a higher body mass index, and a greater prevalence of diabetes and hypertension, compared with patients with HCV-associated cirrhosis, but the 2 groups had similar model for end-stage liver disease (MELD) scores. NASH and CC in patients with MELD scores ≤15 were less likely to progress; these patients were less likely to receive OLT and more likely to die or be taken off the wait list because they were too sick, compared with patients with HCV-associated cirrhosis. The median progression rate among patients with NASH and CC was 1.3 MELD points per year versus 3.2 MELD points per year for the HCV group ( P = .003). Among patients with MELD scores >15, there were no differences among groups in percentage that received transplants or rate of MELD score progression. Hepatocellular carcinoma occurred in 2.7% of patients with NASH and CC per year, compared with 4.7% per year among those with HCV-associated cirrhosis. Conclusions Patients with NASH and CC and low MELD scores have slower disease progression than patients with HCV-associated cirrhosis and are less likely to receive OLT.</description><subject>Cirrhosis</subject><subject>Disease Progression</subject><subject>Fatty Liver</subject><subject>Fatty Liver - complications</subject><subject>Fatty Liver - pathology</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Gastroenterology and Hepatology</subject><subject>Hepatitis C</subject><subject>Hepatitis C, Chronic - complications</subject><subject>Hepatitis C, Chronic - pathology</subject><subject>Hepatitis, Chronic - complications</subject><subject>Hepatitis, Chronic - pathology</subject><subject>Humans</subject><subject>Liver Cirrhosis - complications</subject><subject>Liver Cirrhosis - pathology</subject><subject>Liver Failure - epidemiology</subject><subject>Liver Failure - surgery</subject><subject>Liver Transplantation</subject><subject>Male</subject><subject>Middle Aged</subject><subject>NASH</subject><subject>Non-alcoholic Fatty Liver Disease</subject><subject>Severity of Illness Index</subject><issn>1542-3565</issn><issn>1542-7714</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9Uk2P0zAQjRCIXRZ-ABfkG6eGceLUsZBWqiKgSBUgtoij5TjT1t00ztpJpf57JmpZAQcu_pDfe-M3b5LkNYeUA5-_26d2u0sz4DwFkQLIJ8k1L0Q2k5KLp5dzXsyLq-RFjHuATAklnydXGS8kiDK_TsZvZnDYDZH9dMOOfVncLZnpGlaFUz_4LXbOssqFsPPRRbYIyFYYI1u5e2xPbL0zHS0-4pm-xJ7kBkJWbPDsO1p0R6LQEtg6mC72raFiL5NnG9NGfHXZb5IfHz-sq-Vs9fXT52qxmtkCimHGoWwyqOebUiglFVpj6lKUhcoV3a2Q0tSN5RLAcFtkWV6LjJN3m2dKljXkN8ntWbcf6wM2lowG0-o-uIMJJ-2N03-_dG6nt_6ohYBSgSKBtxeB4B9GjIM-uGixJRfox6hLqTgIVUxIfkba4GMMuHmswkFPaem9prT0lJYGoSkt4rz583uPjN_xEOD9GYDUpKPDoKOltCw2LqAddOPdf-Vv_2Hb1lGgpr3HE8a9H0NH3ddcx0yDvpvGZZoWzgFycpb_AmrPujk</recordid><startdate>20110801</startdate><enddate>20110801</enddate><creator>O'Leary, Jacqueline G</creator><creator>Landaverde, Carmen</creator><creator>Jennings, Linda</creator><creator>Goldstein, Robert M</creator><creator>Davis, Gary L</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20110801</creationdate><title>Patients With NASH and Cryptogenic Cirrhosis Are Less Likely Than Those With Hepatitis C to Receive Liver Transplants</title><author>O'Leary, Jacqueline G ; Landaverde, Carmen ; Jennings, Linda ; Goldstein, Robert M ; Davis, Gary L</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c505t-108d20b6f849979ecaab8485939997c477abdc1700a1c5223b421771c32978b03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Cirrhosis</topic><topic>Disease Progression</topic><topic>Fatty Liver</topic><topic>Fatty Liver - complications</topic><topic>Fatty Liver - pathology</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Gastroenterology and Hepatology</topic><topic>Hepatitis C</topic><topic>Hepatitis C, Chronic - complications</topic><topic>Hepatitis C, Chronic - pathology</topic><topic>Hepatitis, Chronic - complications</topic><topic>Hepatitis, Chronic - pathology</topic><topic>Humans</topic><topic>Liver Cirrhosis - complications</topic><topic>Liver Cirrhosis - pathology</topic><topic>Liver Failure - epidemiology</topic><topic>Liver Failure - surgery</topic><topic>Liver Transplantation</topic><topic>Male</topic><topic>Middle Aged</topic><topic>NASH</topic><topic>Non-alcoholic Fatty Liver Disease</topic><topic>Severity of Illness Index</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>O'Leary, Jacqueline G</creatorcontrib><creatorcontrib>Landaverde, Carmen</creatorcontrib><creatorcontrib>Jennings, Linda</creatorcontrib><creatorcontrib>Goldstein, Robert M</creatorcontrib><creatorcontrib>Davis, Gary L</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Clinical gastroenterology and hepatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>O'Leary, Jacqueline G</au><au>Landaverde, Carmen</au><au>Jennings, Linda</au><au>Goldstein, Robert M</au><au>Davis, Gary L</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Patients With NASH and Cryptogenic Cirrhosis Are Less Likely Than Those With Hepatitis C to Receive Liver Transplants</atitle><jtitle>Clinical gastroenterology and hepatology</jtitle><addtitle>Clin Gastroenterol Hepatol</addtitle><date>2011-08-01</date><risdate>2011</risdate><volume>9</volume><issue>8</issue><spage>700</spage><epage>704.e1</epage><pages>700-704.e1</pages><issn>1542-3565</issn><eissn>1542-7714</eissn><abstract>Background & Aims Many patients with cryptogenic cirrhosis (CC) have other conditions associated with nonalcoholic steatohepatitis (NASH) that put them at risk for complications that preclude orthotopic liver transplantation (OLT). Methods We followed all patients with NASH and CC who were evaluated for OLT (n = 218) at Baylor Simmons Transplant Institute between March 2002 and May 2008. Data were compared with those from patients evaluated for OLT because of hepatitis C virus (HCV)-associated cirrhosis (n = 646). Results Patients with NASH and CC were older, more likely to be female, had a higher body mass index, and a greater prevalence of diabetes and hypertension, compared with patients with HCV-associated cirrhosis, but the 2 groups had similar model for end-stage liver disease (MELD) scores. NASH and CC in patients with MELD scores ≤15 were less likely to progress; these patients were less likely to receive OLT and more likely to die or be taken off the wait list because they were too sick, compared with patients with HCV-associated cirrhosis. The median progression rate among patients with NASH and CC was 1.3 MELD points per year versus 3.2 MELD points per year for the HCV group ( P = .003). Among patients with MELD scores >15, there were no differences among groups in percentage that received transplants or rate of MELD score progression. Hepatocellular carcinoma occurred in 2.7% of patients with NASH and CC per year, compared with 4.7% per year among those with HCV-associated cirrhosis. Conclusions Patients with NASH and CC and low MELD scores have slower disease progression than patients with HCV-associated cirrhosis and are less likely to receive OLT.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>21570483</pmid><doi>10.1016/j.cgh.2011.04.007</doi><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1542-3565 |
ispartof | Clinical gastroenterology and hepatology, 2011-08, Vol.9 (8), p.700-704.e1 |
issn | 1542-3565 1542-7714 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4408909 |
source | MEDLINE; ScienceDirect Journals (5 years ago - present) |
subjects | Cirrhosis Disease Progression Fatty Liver Fatty Liver - complications Fatty Liver - pathology Female Follow-Up Studies Gastroenterology and Hepatology Hepatitis C Hepatitis C, Chronic - complications Hepatitis C, Chronic - pathology Hepatitis, Chronic - complications Hepatitis, Chronic - pathology Humans Liver Cirrhosis - complications Liver Cirrhosis - pathology Liver Failure - epidemiology Liver Failure - surgery Liver Transplantation Male Middle Aged NASH Non-alcoholic Fatty Liver Disease Severity of Illness Index |
title | Patients With NASH and Cryptogenic Cirrhosis Are Less Likely Than Those With Hepatitis C to Receive Liver Transplants |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-15T15%3A39%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Patients%20With%20NASH%20and%20Cryptogenic%20Cirrhosis%20Are%20Less%20Likely%20Than%20Those%20With%20Hepatitis%20C%20to%20Receive%20Liver%20Transplants&rft.jtitle=Clinical%20gastroenterology%20and%20hepatology&rft.au=O'Leary,%20Jacqueline%20G&rft.date=2011-08-01&rft.volume=9&rft.issue=8&rft.spage=700&rft.epage=704.e1&rft.pages=700-704.e1&rft.issn=1542-3565&rft.eissn=1542-7714&rft_id=info:doi/10.1016/j.cgh.2011.04.007&rft_dat=%3Cproquest_pubme%3E879104959%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=879104959&rft_id=info:pmid/21570483&rft_els_id=1_s2_0_S1542356511003879&rfr_iscdi=true |